Intercept: BRIEF---EMA recommends revoking conditional authorization for Ocaliva
The European Medicines Agency's (EMA) human medicines committee (CHMP) has concluded its review of Intercept Pharmaceuticals' Ocaliva (obeticholic acid) and has recommended that the medicine's marketing authorization be revoked
Read full article »
Intercept is a New Jersey-based biopharmaceutical company that researches and develops novel therapeutics for the treatment of patients with non-viral liver diseases.
Read more